Vistagen Therapeutics (VTGN) and Targeted Medical Pharma (TRGM) Financial Review

Targeted Medical Pharma ( OTCMKTS:TRGM ) and Vistagen Therapeutics ( NASDAQ:VTGN ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.

Risk & Volatility

Targeted Medical Pharma has a beta of -0.52, meaning that its share price is 152% less volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500.

Profitability

This table compares Targeted Medical Pharma and Vistagen Therapeutics’ net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Targeted Medical Pharma N/A N/A N/A Vistagen Therapeutics N/A -581.50% -255.52% Earnings & Valuation

This table compares Targeted Medical Pharma and Vistagen Therapeutics’ top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Targeted Medical Pharma N/A N/A N/A N/A N/A Vistagen Therapeutics $1.25 million 34.36 -$14.34 million ($1.11) -1.24 Targeted Medical Pharma has higher earnings, but lower revenue than Vistagen Therapeutics.

Insider and Institutional Ownership

8.7% of Vistagen Therapeutics shares are held by institutional investors. 69.2% of Targeted Medical Pharma shares are held by company insiders. Comparatively, 13.4% of Vistagen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Targeted Medical Pharma and Vistagen Therapeutics, as reported by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Targeted Medical Pharma 0 0 0 0 N/A Vistagen Therapeutics 0 0 4 0 3.00 Vistagen Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 624.64%. Given Vistagen Therapeutics’ higher possible upside, analysts clearly believe Vistagen Therapeutics is more favorable than Targeted Medical Pharma.

Summary

Vistagen Therapeutics beats Targeted Medical Pharma on 5 of the 8 factors compared between the two stocks.

About Targeted Medical Pharma Targeted Medical Pharma logo Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers’ compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.

About Vistagen Therapeutics Vistagen Therapeutics logo VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company’s lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of drug rescue NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Receive News & Ratings for Targeted Medical Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Targeted Medical Pharma and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *